H2 reversal collapses FY25 NPAT to NZ$0.3m from NZ$37.2m

What changed

Marlin's FY25 total income fell to NZ$5.9m from NZ$42.9m (-86.3%), and NPAT collapsed to NZ$0.3m from NZ$37.2m (-99.1%). Because Marlin is a listed investment company, "revenue" is effectively investment income and fair-value movements, so the drop reflects portfolio performance rather than trading activity. Operating cash flow of NZ$7.2m was positive, cash ended at NZ$3.2m, and total equity closed at NZ$212.1m on total assets of NZ$214.9m with only NZ$2.9m of liabilities. The final dividend was cut to 1.88 cents per share from 2.07 cents (-9.2%).

What matters

• The result is really a second-half reversal, not a full-year earnings story. HY25 carried NZ$11.3m of revenue and NZ$8.1m of NPAT; the FY25 prints of NZ$5.9m and NZ$0.3m imply a second half of roughly -NZ$5.4m revenue and -NZ$7.7m NPAT. Almost all of the interim gain was given back.
• Tax distortion makes PBT the cleaner read. PBT of NZ$2.5m was cut to NZ$0.3m NPAT by NZ$2.2m of tax, an 86.7% effective rate. Prior-year PBT was not disclosed, so a growth gap is not computable, but the NPAT line overstates the deterioration in underlying portfolio economics for the year.
• Capital allocation is running ahead of earnings. The 1.88c final dividend alone implies a payout ratio of ~1,253% of FY25 NPAT on the calculation pass; distributions are being funded from NAV/operating cash rather than current-year earnings, which is normal for an LIC but tightens the link between NAV direction and sustainable distribution.

Expectations

No quantitative targets, forward-work metric, or NTA disclosure were extracted, so there is no management benchmark to test the result against. Seasonality is not meaningful for an investment vehicle — the HY25-to-FY25 shape (first-half share of 192% of full-year revenue and 2,439% of full-year NPAT) is a mark-to-market reversal, not a seasonal pattern. The release therefore supports a read that H2 market/portfolio moves wiped out interim gains, but does not support any view on FY26 portfolio direction.

Quality of result

Quality is low in the sense that the earnings are essentially mark-to-market and have already proven reversible within a single year. The NZ$7.2m of operating cash inflow is larger than PBT and larger than NPAT, but for an LIC that line captures dividend/interest receipts and realised trading rather than recurring operating cash in the industrial sense, so it should not be treated as a clean "cash-backed earnings" signal. There are no non-recurring adjustments, no non-GAAP reconciliations, and no segment disclosure — only statutory figures — so there is little balance-sheet assistance, but also little durable evidence of underlying run-rate economics.

Unresolved

• What drove the H2 reversal — which holdings marked down, and by how much — and how the portfolio is positioned at year-end.
• Why the effective tax rate was 86.7%, and whether that reflects non-deductible losses, imputation timing, or PIE-related adjustments.
• NTA per share at balance date and the share-price discount/premium, neither of which were extracted.
• The full-period dividend (the 1.88c is the final component only) and how sustained distributions interact with a shrinking equity base if FY26 returns stay weak.
• Any concentration, leverage, or FX sensitivity in the portfolio beyond the NZ$1m FX effect on cash.

This briefing cannot assess NAV performance, portfolio composition, or total shareholder return, because the extracted dataset contains only headline P&L, cash, and balance-sheet aggregates.

Key metrics

Analytical metrics

This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.